|Table of Contents|

Insights into the Binding of Ketone Mannich Base DerivativesInhibitors to AChE by Molecular Dynamics Simulation(PDF)

《南京师大学报(自然科学版)》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2018年03期
Page:
59-
Research Field:
·化学·
Publishing date:

Info

Title:
Insights into the Binding of Ketone Mannich Base DerivativesInhibitors to AChE by Molecular Dynamics Simulation
Author(s):
Wang YaliZhao TengtengZhu Xiaolei
State Key Laboratory of Materials-Oriented Chemical Engineering,College of Chemistry and Chemical Engineering,Nanjing University of Technology,Nanjing 210009,China
Keywords:
ketone Mannich base derivatives inhibitorsAChEmolecular dynamics simulationbinding free energy
PACS:
O643.1
DOI:
10.3969/j.issn.1001-4616.2018.03.010
Abstract:
We investigate the binding mode and the interaction mechanism of three ketone Mannich base derivative inhibitors(they are marked as M1,M2,and M3 hereunder)with AChE in terms of molecular docking(autodock),molecular dynamics simulation(MD)and binding free energy calculation(MM/PBSA)methods. The results of binding free energy correspond to the experimental bioactivity data(IC50 values)of three inhibitors. The Van der Waals interaction is the main driving force in binding affinity of the three inhibitors with AChE. Although the binding modes of M2 and M3 are similar,they are different from that of M1/AChE,which are reflected in the energy analysis between the three inhibitors and the surrounding residues. Residues W84 and E82 are the key residues that can distinguish the bioactivity of M1,M2 and M3,respectively.

References:

[1] BLENNOW K,LEON M J D,ZETTERBERG H. Alzheimer’s disease[J]. Lancet,2006,368:387-403.
[2]PRINCE M,COMAS-HERRERA A,KNAPP M,et al. World Alzheimer Report 2016:improving healthcare for people with dementia. Coverage,quality and costs now and in the future[R]. London:Alzheimer’s Disease International,2016.
[3]KASA P,RAKONCZAY Z,GULYA K. The cholinergic system in Alzheimer’s disease[J]. Trends in neurosciences,1997,52:511-535.
[4]DVIR H,SILMAN I,ROSENBERRY T L,et al. Acetylcholinesterase:from 3D structure to function[J]. Chemico-biological interactions,2010,187:10-22.
[5]NELSON L,TABET N. Slowing the progression of Alzheimer’s disease; what works?[J]. Ageing research reviews,2015,23:193-209.
[6]LI Y,QIANG X M,LUO L,et al. Multitarget drug design strategy against Alzheimer’s disease:Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties[J]. Bioorganic and medicinal chemistry,2017,25:714-726.
[7]LI Y,QIANG X M,LUO L,et al. Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition,anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer’s disease[J]. European journal of medicinal chemistry,2016,126:762-775.
[8]LEMES L F N,DE ANDRADE RAMOS G,DE OLIVEIRA A S,et al. Cardanol-derived AChE inhibitors:towards the development of dual binding derivatives for Alzheimer’s disease[J]. European journal of medicinal chemistry,2016,108:687-700.
[9]FRISCH M J,TRUCKS G W,SCHLEGEL H B,et al. Gaussian 09[Z]. Wallingford:Gaussion Inc.,2009.
[10]MORRIS G M,HUEY R,LINDSTROM W,et al. AutoDock4 and AutoDockTools4:automated docking with selective receptor flexibility[J]. Journal of computational chemistry,2009,30:2785-2791.
[11]JIANG N,MA J. Conformational simulations of aqueous solvated alpha-conotoxin GI and its single disulfide analogues using a polarizable force field model[J]. Journal of physical chemistry A,2008,112(40):9854-9867.
[12]WANG J M,WOLF R M,CALDWELL J W,et al. Development and testing of a general amber force field[J]. Journal of computational chemistry,2004,25:1157-1174.
[13]GENHEDEN S,RYDE U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities[J]. Expert opinion on drug discovery,2015,10:449-461.
[14]RAFI S B,CUI G L,SONG K,et al. Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI,the E. coli enoyl reductase[J]. Journal of medicinal chemistry,2006,49(15):4574-4580.
[15]WALLACE A C,LASKOWSKI R A,THORNTON J M. Ligplot:a program to generate schematic diagrams of protein-ligand interactions[J]. Protein engineering,1995,8(2):127-134.

Memo

Memo:
-
Last Update: 2018-11-19